Falk G. Bechara, MD, discusses long-term tunnel control, structural damage, and the evolving role of biologics and surgery in HS care.

New dermatology research explores hidden steroids in OTC products, infant eczema, melanoma prevention, cutaneous lymphoma, and pediatric AD.

An analysis of 633 skincare brands found gaps in evidence, safety information, and claim support, raising questions about what patients can verify online.

This week’s review highlights pediatric oral minoxidil guidance, alopecia areata imaging, inherited skin disorder growth patterns, total-body photography, and radiofrequency microneedling for rosacea.

The novel oral helicase-primase inhibitor demonstrated significantly higher rates of complete lesion healing compared with investigator’s choice treatment in the phase 3 PRIOH-1 trial.

Prospective data suggest DecisionDx-Melanoma may help refine SLNB decisions and identify recurrence risk beyond conventional staging.

Galderma has agreed to acquire ZO Skin Health for $1.5 billion, adding the physician-dispensed skincare brand to a portfolio that already includes Cetaphil and Alastin.

SYX-5219 improved disease severity and itch in a Phase 1b trial of adults with moderate to severe atopic dermatitis.